What should I pay attention to while taking larotrectinib?

Larotrectinib is a highly selective oral TRK inhibitor targeting NTRK gene fusion. It is suitable for the treatment of a variety of advanced solid tumors caused by NTRK gene fusion. As a precision treatment drug, larotinib has shown good efficacy and tolerability in practical applications. However, there are some important matters that patients need to pay special attention to in order to maximize the efficacy and reduce the occurrence of adverse reactions while taking larotrectinib.

First of all, patients should ensure that they have confirmed the presence of NTRK gene fusion through professional genetic testing before taking larotrectinib. This is because the mechanism of action of larotrectinib is to specifically inhibit the activity of the NTRK gene fusion protein and is ineffective against other types of tumor mutations. Therefore, direct use of larotrectinib without genetic testing will not only fail to bring therapeutic benefits, but may also lead to delayed disease progression. Patients should make a scientific and reasonable decision on whether to use this drug under the guidance of a doctor and based on the genetic test report.

Secondly, the medication time, dosage and usage of larotrectinib need to strictly follow the doctor's prescription. It is usually recommended to take larotrectinib twice a day, once in the morning and once in the evening, and try to take it at a fixed time to maintain a stable drug concentration in the body. Larotrectinib can be taken with food or on an empty stomach, but patients should avoid taking it with grapefruit or foods containing grapefruit ingredients, because grapefruit may affect the metabolism of larotrectinib in the body, resulting in abnormally high drug concentrations, thereby increasing the risk of side effects. In addition, patients should try to avoid adjusting the dose on their own or suddenly stopping the medication while taking the medication. If they encounter serious adverse reactions, they should inform their doctor in time, and the doctor will decide whether to adjust the dose or suspend treatment after evaluation.

Third, while taking larotrectinib, patients need to pay close attention to changes in their physical condition, especially drug-related adverse reactions. Common adverse reactions include fatigue, nausea, vomiting, constipation, dizziness, weight gain, elevated transaminases, etc. Most adverse reactions are mild to moderate and can be improved with appropriate treatment. However, some patients may experience serious adverse reactions, such as abnormal liver function, neurological problems (such as balance disorders, difficulty in movement coordination, etc.) or cardiac problems (such as QT interval prolongation). Therefore, it is very necessary to conduct liver function tests, electrolyte monitoring and electrocardiogram examinations regularly. Once abnormal indicators appear, they should be dealt with in a timely manner under the guidance of a doctor.

Finally, during larotrectinib treatment, patients should develop good living habits to assist the drug in achieving better therapeutic effects. Maintaining a balanced diet, reasonable work and rest, moderate exercise, and avoiding infections are very important basic measures. At the same time, you should avoid taking drugs that may have drug interactions with larotrectinib, such as strongCYP3A4Inhibitors or inducers, etc., unless prior consent of a physician is obtained. In addition, female patients should take effective contraceptive measures during treatment and at least one month after the last dose, and male patients should take effective contraceptive measures during treatment and at least three months after the last dose to prevent potential harm to the fetus. If the patient requires surgery during treatment, the surgeon should be informed in advance that larotrectinib is being used so that a safer perioperative management plan can be developed.

In short, larotrectinib, as an important drug for precision treatment of NTRK gene fusion tumors, can bring new treatment hope to patients. However, in order to use larotrectinib safely and effectively, patients need to use the medication regularly under the guidance of professional doctors, closely monitor body reactions, deal with possible adverse reactions in a timely manner, and conduct comprehensive management combined with a healthy lifestyle. Only in this way can the therapeutic potential of larotrectinib be maximized, extending survival and improving quality of life.

Reference materials:https://www.vitrakvi.com/